focus -WSS

focus

author：entertainment 2025-09-27 19:29:30 - browse：4285

Most everything is looking up for Orexo, the company reported on its second quarter earnings call on Tuesday. That is, everything but its digital therapies pipeline.

The Swedish pharmaceutical company, which makes almost all of its money from U.S. sales of its drug for opioid dependence, notched a number of important victories in the quarter: It successfully defended its patents in a case against Sun Pharmaceuticals, it resolved a packaging issue that was holding up the approval of its long-acting rescue medication, and it grew revenues for Zubsolv, its most important product. The company trimmed its losses to 12.6 million SEK, or $1.2 million, and executives reported that with fewer one-time expenses on the horizon, profitability was “in sight.”

“We are at an exciting turning point for the company and I hope our self confidence and optimism is something that you can share,” CEO Nikolaj Sørensen said on the company’s earnings call while cautioning that “there’s a lot more work to be done.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Stanford updates investigation of president’s past research

explore

WSS

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

Former Georgia lieutenant governor says he received grand jury subpoena

CDC launches VaccineFinder tool to locate Covid

Resistance to cancer drugs: A new genetic explanation

Lindsay Lohan welcomes 1st child with husband Bader Shammas

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

leisure time

focus

hotspot

Tori Bowie and the unacceptable rates of Black maternal death

Plane’s emergency slide plummets from sky, hits Chicago home

Malaria cases in Florida and Texas: Here’s what you need to know

Seattle police shoot person suspected in downtown stabbing

How one medical school became remarkably diverse

An Ebola outbreak presents a new mystery involving children

Supreme Court strikes down use of affirmative action

Stanford president to resign after investigation of research

Moonlake's readout produced a cash windfall. Risks remain

'Of course' Trump lost the 2020 election, DeSantis says after years of hedging

focus

Norman Reedus' Daryl Dixon

New warning issued for rebooking air travel after delays, cancellations

Actors' union, Hollywood studios squabble over which side to blame as strike enters 5th day

Ohioans vote in high

Why the Crimean Bridge is key to Russia's war in Ukraine

Actors' union, Hollywood studios squabble over which side to blame as strike enters 5th day

knowledge

explore

focus

explore